Nebenwirkungen · DuoResp Spiromax
DuoResp Spiromax 320 micrograms/9 micrograms inhalation powder · Abschnitt 4.8 · PDF-Seite 25–26
HOS-215234 · Präparat HOS-155404
Since DuoResp Spiromax contains both budesonide and formoterol, the same pattern of adverse reactions as reported for these substances may occur. No increased incidence of adverse reactions has been seen following concurrent administration of the two compounds. The most common adverse reactions are pharmacologically predictable adverse reactions of β2 adrenoceptor agonist therapy, such as tremor and palpitations. These tend to be mild and usually disappear within a few days of treatment. In a 3-year clinical trial with budesonide in COPD, skin bruises and pneumonia occurred at a frequency of 10% and 6%, respectively, compared with 4% and 3% in the placebo group (p<0.001 and p<0.01, respectively). 25 Tabulated list of adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-24T17:52:00Z · SHA-256 42079bf4b69044dc4d633d260c46172c183d9e017cb9bfa60f9313d810771afa · Passage c54c5a2843d5b9a9b419fa748007fe3d5abc0730a3f3d75f8865ffdc6ea05d63 · Zeichen 31–830 im Abschnitt